NCT06501326View on ClinicalTrials.gov

Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

February 28, 2025

Conditions
Non-alcoholic Fatty Liver DiseaseObesity
Interventions
DRUG

Liraglutide

After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.

DRUG

Orlistat

After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.

Trial Locations (1)

Unknown

RECRUITING

Affiliated Hospital of Nantong University, Nantong

All Listed Sponsors
collaborator

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

lead

Affiliated Hospital of Nantong University

OTHER